EMEA-001474-PIP02-16-M02
Key facts
| Invented name |
Keytruda
|
| Active substance |
Pembrolizumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0534/2021
|
| PIP number |
EMEA-001474-PIP02-16-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Hodgkin lymphoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe), Inc.
E-mail: pip.information@merck.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|